INS and type 2 diabetes mellitus: In a recent publication, GIP-receptor agonists were found still to increase insulin levels in subjects with newly diagnosed type-2 diabetes, but postprandial glucose excursions were not improved, possibly due to a simultaneous glucagonotropic effect (Chia et al., 2009).